Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.45
Industry P/E
--
Debt to Equity
0
ROE
-2.4 %
ROCE
-152.09 %
Div. Yield
0 %
Book Value
5027509.11
EPS
-3823268.8
CFO
$-82.73 Mln
EBITDA
$-97.96 Mln
Net Profit
$-101.26 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Evoke Pharma (EVOK)
| -51.36 | -43.72 | -51.79 | -61.88 | -66.09 | -59.44 | -45.67 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Evoke Pharma (EVOK)
| -64.62 | -60.82 | -78.68 | 59.26 | -34.68 | 9.68 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat... symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. Address: 420 Stevens Avenue, Solana Beach, CA, United States, 92075 Read more
Co-Founder, President, CEO, COO, Secretary, Treasurer & Director
Mr. Matthew J. D'Onofrio MBA
Co-Founder, President, CEO, COO, Secretary, Treasurer & Director
Mr. Matthew J. D'Onofrio MBA
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Evoke Pharma Inc (EVOK) stood at $ 17,519,007 Mln as on 31-Dec-24
The share price of Evoke Pharma Inc (EVOK) is $2.15 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Evoke Pharma Inc (EVOK) has given a return of -66.09% in the last 3 years.
Evoke Pharma Inc (EVOK) has a market capitalisation of $ 3 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Evoke Pharma Inc (EVOK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Evoke Pharma Inc (EVOK) and enter the required number of quantities and click on buy to purchase the shares of Evoke Pharma Inc (EVOK).
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. Address: 420 Stevens Avenue, Solana Beach, CA, United States, 92075
The CEO & director of Mr. Matthew J. D'Onofrio MBA. is Evoke Pharma Inc (EVOK), and CFO & Sr. VP is Mr. Matthew J. D'Onofrio MBA.
There is no promoter pledging in Evoke Pharma Inc (EVOK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Evoke Pharma Inc. (EVOK) | Ratios |
|---|---|
|
Return on equity(%)
|
-152.09
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-52.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Evoke Pharma Inc (EVOK) was $0 Mln.
